An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

This article was originally posted on the DSW Blog.

Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The Sabin Product Development Partnership, and the Global Network for Neglected Tropical Diseases.

Reposted with permission from the TAMEST blog, which is run by the Academy of Medicine, Engineering & Science of Texas. 

Neglected Tropical Diseases (NTDs) are an important health issue in countries around the world. Most people don’t think about them at all, let alone know that some NTDs are also prevalent in the United States. The emerging threat of NTDs at home has been gaining attention recently, such as in this recent article, which appeared online in Discover.
Earlier this week 13 pharmaceutical companies*, together with several government and nongovernmental organizations**, pledged to find solutions to eliminate or control 10 neglected tropical diseases (NTDs) by the year 2020. At an event in London, pharmaceutical companies committed to invest in research and development (R&D) to find new treatments for NTDs along with increasing donations of existing drugs.

Great news in the world of global health! A recent clinical trial for an experimental malaria vaccine has yielded successful results in protecting a large number of children against malaria with minimal side effects.